IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

(marketscreener.com) -   IDE161 is being developed as a potential first-in-class PARG inhibitor for patients having tumors with HRD, with an initial focus in BRCA1/2-mutant Breast and Ovarian Cancer-   Proposed clinical development plan for IDE161 to be highlighted in Investor R&D Day webcast being hosted by IDEAYA today, December 12, 2022,...https://www.marketscreener.com/quote/stock/IDEAYA-BIOSCIENCES-INC-58457878/news/IDEAYA-Biosciences-Announces-Submission-of-IND-Application-to-the-U-S-FDA-for-PARG-Development-Cand-42525746/?utm_medium=RSS&utm_content=20221212